Alnylam received US FDA approval for its first-in-class RNAi treatment, Onpattro, but a spokesperson confirmed manufacturing for the treatment is a complicated affair.
Alnylam has both acquired Merck & Co. subsidiary Sirna therapeutics and extended an alliance with Genzyme in order to advance its small interfering RNA (siRNA) delivery programme.
A new alliance between Merck & Co and Alnylam, a specialist in
the development of therapeutics based on RNA interference (RNAi)
could fast-track the first drug in this class though to market.